1. Home
  2. INSM vs RTO Comparison

INSM vs RTO Comparison

Compare INSM & RTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • RTO
  • Stock Information
  • Founded
  • INSM 1988
  • RTO 1925
  • Country
  • INSM United States
  • RTO United Kingdom
  • Employees
  • INSM N/A
  • RTO N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • RTO Business Services
  • Sector
  • INSM Health Care
  • RTO Consumer Discretionary
  • Exchange
  • INSM Nasdaq
  • RTO Nasdaq
  • Market Cap
  • INSM 14.3B
  • RTO 12.2B
  • IPO Year
  • INSM 2000
  • RTO N/A
  • Fundamental
  • Price
  • INSM $76.29
  • RTO $22.89
  • Analyst Decision
  • INSM Strong Buy
  • RTO Hold
  • Analyst Count
  • INSM 16
  • RTO 1
  • Target Price
  • INSM $95.36
  • RTO N/A
  • AVG Volume (30 Days)
  • INSM 1.5M
  • RTO 1.1M
  • Earning Date
  • INSM 05-08-2025
  • RTO 03-26-2025
  • Dividend Yield
  • INSM N/A
  • RTO 2.35%
  • EPS Growth
  • INSM N/A
  • RTO N/A
  • EPS
  • INSM N/A
  • RTO 0.15
  • Revenue
  • INSM $363,707,000.00
  • RTO $6,805,463,398.00
  • Revenue This Year
  • INSM $30.31
  • RTO $6.81
  • Revenue Next Year
  • INSM $118.39
  • RTO $3.82
  • P/E Ratio
  • INSM N/A
  • RTO $29.63
  • Revenue Growth
  • INSM 19.17
  • RTO 1.14
  • 52 Week Low
  • INSM $21.92
  • RTO $20.60
  • 52 Week High
  • INSM $84.91
  • RTO $34.07
  • Technical
  • Relative Strength Index (RSI)
  • INSM 46.23
  • RTO 46.62
  • Support Level
  • INSM $76.05
  • RTO $21.76
  • Resistance Level
  • INSM $79.12
  • RTO $23.42
  • Average True Range (ATR)
  • INSM 2.52
  • RTO 0.37
  • MACD
  • INSM -0.02
  • RTO 0.19
  • Stochastic Oscillator
  • INSM 38.63
  • RTO 81.21

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About RTO Rentokil Initial plc

Rentokil Initial is the largest global provider of route-based pest-control and commercial hygiene services, operating in 83 countries. The group also offers a range of specialist route-based services including office and commercial space plant care, property care, and workwear rentals. The group has a diverse client base that includes global food producers, hotel chains, industrial goods businesses, restaurants, and individual residential customers.

Share on Social Networks: